Cogent Biosciences Inc

Healthcare · Biotechnology

30.40$ -1.6% vs. previous close Closing price · As of: Oct 6, 2026

Statements

Balance Sheet

Cogent Biosciences Inc (COGT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 835 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow Ratios

Annual Quarterly

Amounts Change % Common size %

Last 12 Full history

Download as CSV

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet COGT
Line item	Q3 15	Q3 16	Q1 17	Q2 17	Q3 17	Q4 17	Q1 18	Q2 18	Q3 18	Q4 18	Q1 19	Q2 19	Q3 19	Q4 19	Q1 20	Q2 20	Q3 20	Q4 20	Q1 21	Q2 21	Q3 21	Q4 21	Q1 22	Q2 22	Q3 22	Q4 22	Q1 23	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26	Q2 26
Total Assets	–	311	–	–	56	49	43	103	95	86	81	69	58	49	39	31	140	251	238	229	215	232	207	366	332	301	263	392	355	313	476	430	384	328	284	275	426	938	903	835
Current Assets	–	42	–	–	51	42	35	97	89	81	70	59	46	41	31	24	133	245	232	221	208	223	195	331	296	265	226	335	286	271	442	370	342	296	253	245	397	910	878	805
Cash	–	10	–	–	31	28	26	47	49	56	59	56	46	37	30	21	129	242	231	218	203	220	191	326	141	140	161	214	87	53	216	88	97	98	126	128	125	312	241	181
Cash & Short-Term Investments	–	10	–	–	48	41	32	94	87	79	67	56	46	37	30	21	129	242	231	218	203	220	191	326	289	259	220	329	279	266	436	363	336	287	246	238	391	901	866	792
Receivables	–	28	–	–	1.5	0.8	1.6	1.2	1.4	1.7	2.0	1.5	0.9	2.0	0.0	0.0	0.0	0.0	–	–	–	–	–	–	4.8	–	4.8	4.8	–	–	–	–	–	–	–	–	–	–	–	–
Inventory	–	–	–	–	–	0.1	0.1	0.1	–	–	–	–	-2.1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Property, Plant & Equipment	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	5.2	4.7	4.3	3.9	1.3	1.7	2.1	3.6	30	7.8	9.0	9.1	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	166	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Intangible Assets	–	99	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Total Liabilities	–	89	–	–	22	21	28	26	27	26	32	30	29	18	13	12	24	16	11	16	18	18	19	47	42	45	40	44	53	56	54	57	69	72	65	120	123	301	295	302
Current Liabilities	–	28	–	–	11	11	23	25	26	25	26	24	24	13	9.3	8.3	20	13	8.2	14	17	17	18	28	24	27	21	26	35	38	37	40	53	56	49	58	62	64	58	59
Short-Term Debt	–	2.3	–	–	–	2.8	–	–	–	3.8	1.5	1.5	1.6	1.6	1.7	1.7	2.0	2.1	2.1	2.2	2.3	2.3	2.4	9.1	2.0	1.4	0.9	1.2	1.3	1.4	1.4	1.5	1.5	1.6	1.6	1.7	1.7	1.5	1.4	1.5
Accounts Payable	–	16	–	–	2.0	1.3	3.1	1.7	0.8	1.5	1.8	1.7	1.6	3.2	0.6	0.6	0.6	0.7	0.3	2.0	4.3	3.5	4.0	3.5	4.1	5.8	4.2	7.2	9.9	11	16	9.0	15	12	14	17	16	9.5	14	7.5
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	44	44	223	223	223
Shareholders' Equity	–	222	–	–	34	28	16	77	68	60	49	40	29	32	26	19	116	235	227	213	197	214	188	319	290	256	224	348	303	258	422	373	315	256	219	155	302	636	608	532
Retained Earnings	–	-109	–	–	-45	-51	-64	-73	-83	-92	-104	-114	-126	-124	-130	-137	-187	-199	-210	-227	-246	-271	-302	-337	-372	-411	-450	-494	-549	-604	-662	-721	-792	-859	-931	-1,005	-1,086	-1,188	-1,286	-1,382
Shares Outstanding	3.8	13	7.4	7.4	7.4	5.9	6.6	7.3	7.5	7.5	7.5	7.6	7.7	7.7	7.5	7.8	9.9	10	35	38	40	44	45	49	70	70	71	75	86	87	95	99	110	110	114	114	140	161	171	171

Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Balance Sheet

Cookie settings